Multiple system atrophy (MSA) is a sporadic neurodegenerative disease characterized by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction [1]. The distribution of pathology classically encompasses three functional systems in the central nervous system – the striatonigral system, olivopontocerebellar system and autonomic system – impacting on movement, muscle control, blood pressure, heart rate and bladder function [2,3]. MSA affects equally both men and women primarily in their 50s, although it can strike as early as 30s. The progression of disease is rapid and patients are confined to bed within 5 years of onset of symptoms and death results within ~9 years [4]. MSA shares some similarities with Parkinson’s disease (PD) with overlapping clinical presentation of motor impairments, and as such, MSA is commonly misdiagnosed as PD [1,5]. However, in comparison to PD, MSA is relatively rare, with a prevalence rate of 3–4 per 100,000 [6–8]. The aetiology in the central nervous system – the striatonigral system, olivopontocerebellar system and autonomic system – impacting on movement, muscle control, blood pressure, heart rate and bladder function [2,3]. MSA affects equally both men and women primarily in their 50s, although it can strike as early as 30s. The progression of disease is rapid and patients are confined to bed within 5 years of onset of symptoms and death results within ~9 years [4]. MSA shares some similarities with Parkinson’s disease (PD) with overlapping clinical presentation of motor impairments, and as such, MSA is commonly misdiagnosed as PD [1,5]. However, in comparison to PD, MSA is relatively rare, with a prevalence rate of 3–4 per 100,000 [6–8]. The aetiology in the central nervous system – the striatonigral system, olivopontocerebellar system and autonomic system – impacting on movement, muscle control, blood pressure, heart rate and bladder function [2,3]. MSA affects equally both men and women primarily in their 50s, although it can strike as early as 30s. The progression of disease is rapid and patients are confined to bed within 5 years of onset of symptoms and death results within ~9 years [4]. MSA shares some similarities with Parkinson’s disease (PD) with overlapping clinical presentation of motor impairments, and as such, MSA is commonly misdiagnosed as PD [1,5]. However, in comparison to PD, MSA is relatively rare, with a prevalence rate of 3–4 per 100,000 [6–8]. The aetiology
of MSA is largely unknown, although studies point to a possible genetic component [9,10], as well as environmental factors capable of increasing susceptibility [5,11]. Based on current information the sequence of pathological events of MSA is now recognized as abnormal protein redistributions in oligodendrocytes first, followed by myelin dysfunction and then neurodegeneration and loss of neurons (Fig. 1).

NEUROPATHOLOGY OF MSA

Current understanding of MSA neuropathology is that both grey and white matter pathology occur in the form of neurodegeneration, gliosis, myelin loss and axonal degeneration [12]. These changes also typically occur in specific anatomical locations that include subcortical regions within the olivopontocerebellar pathway (e.g. inferior olives, pons, cerebellum), strionigral pathway (e.g. striatum and substantia nigra), and in autonomic nuclei within the spinal cord and brainstem [13,14]. Furthermore, although earlier studies reported the cerebral cortex was spared in MSA, later studies have reported decreased neuronal density in the primary and supplementary motor cortex of MSA patients [14,15], as well as atrophy occurring in regions within the frontal lobe [7]. Therefore, as exemplified by these studies, neuropathological changes occur widely throughout various subcortical and cortical regions in MSA brains.

However, while these neuropathological changes are commonly observed in post-mortem brains of MSA patients [13], the most consistent pathological hallmark of MSA is glial cytoplasmic inclusions (GCIs) (Fig. 2). These inclusions are variably shaped, filamentous protein aggregates that form in the cytoplasm of oligodendrocytes, which are thought to play a primary role in the pathogenesis of MSA [12], as their anatomical distribution correlates with regions where neurodegeneration occurs [16,17]. In terms of their constituents, GCIs are composed of a multitude of proteins including ubiquitin, the heat shock protein αβ-crystallin, and the microtubule proteins, α- and β-tubulin [18]. However, the predominant constituent is the α-synuclein protein [19,20]. Normally, α-synuclein is mainly localized to the presynaptic terminals of neurons as a non-phosphorylated, soluble and unfolded monomer [8,21]. α-Synuclein is putatively involved in regulating synaptic plasticity [22] and presynaptic events [23,24], although gaps in our understanding of its normal physiological role still remain. Nonetheless, the presence of these α-synuclein aggregates thus places MSA in a category of diseases known as α-synucleinopathies alongside PD and Lewy body dementia, which are similarly characterized by abnormal α-synuclein aggregates.

α-SYNUCLEIN PATHOLOGY AND NEURODEGENERATION

In contrast to the neuronal localization and normal structure of α-synuclein in healthy brains [8,21], during the MSA disease process, the localization and structure of α-synuclein is vastly altered. As suggested by the location of GCIs in MSA,
α-synuclein becomes aberrantly translocated to the cytoplasm of oligodendrocytes. However, the mechanism by which this occurs remains unknown, although it is possible neurons secrete α-synuclein into the extracellular environment, which is subsequently taken up by surrounding oligodendrocytes [12,25-27]. Nonetheless, α-synuclein also undergoes multiple structural modifications including phosphorylation at serine residue 129, while also developing an ordered β-sheet-rich secondary structure, with the latter being facilitated by an increase in surrounding lipid concentrations [28-31]. Together, these structural changes are thought to promote the self-aggregation of α-synuclein into intermediate species (e.g. oligomers and protofibrils) that precede the formation of mature fibrils [32,33].

The formation of GCIs and intermediate species of α-synuclein also cause alterations in α-synuclein function in MSA. That is, rather than contributing to the regulation of synaptic plasticity and presynaptic events [22-24], α-synuclein appears to contribute towards neurodegeneration, albeit the precise mechanism(s) that induces this remains unclear. Potential mechanisms suggested by in vitro studies of other α-synucleinopathies include oxidative stress and neurotoxicity evoked by mitochondrial and lysosomal damage [34,35], as well as impaired transport of crucial presynaptic proteins (e.g. synapsin-1), which cause synaptic dysfunction to contribute towards neuronal death [36]. Furthermore, another hypothesis posits that annular shaped intermediate species form abnormal membranous pore-like channels that are capable of altering membrane permeability and reducing the integrity of presynaptic vesicles [37]. This is then subsequently thought to promote dysregulated ion homeostasis and dopamine release respectively, to cause the excessive release of dopamine and ions such as calcium into the extracellular space, to ultimately result in neurodegeneration induced by neurotoxicity.

The downstream consequences of these α-synuclein induced mechanisms of neurodegeneration have also been illustrated through transgenic mice overexpressing human α-synuclein (e.g. under the control of the murine myelin basic protein promoter). More specifically, these mice demonstrated selective accumulation and aggregation of α-synuclein in oligodendrocytes that preceded neurodegeneration, as well as gliosis, myelin loss and axonal abnormalities [38-40]. The severity of these neuropathological features also correlated with the degree of α-synuclein overexpression, whereby mice expressing higher amounts of α-synuclein exhibited more severe neuropathological changes and vice versa, ultimately providing further evidence for a causative relationship between α-synuclein and downstream neuropathological changes. Furthermore, these consequences from α-synuclein accumulation and aggregation also appeared sufficient to produce motor impairments and induce death, which draws similarities with the clinical profile of MSA patients [1,38,39].

Therefore, given the apparent ability of α-synuclein to cause a variety of neuropathological abnormalities that are similarly observed in MSA patients, alterations in its localization and function have been incorporated into the current working hypothesis of MSA pathogenesis. This working hypothesis suggests that the initiating culprit of MSA pathogenesis is the uptake of α-synuclein into oligodendrocytes, and its subsequent aggregation into GCIs. The latter is facilitated by p25α, which is normally involved in myelination and stabilization of microtubules [41], but re-localized from myelin to cell soma during the early stages of MSA, where it acts as potent stimulator of α-synuclein aggregation to promote GCI formation [42,43]. The relocation of p25α and the formation of GCIs then leads to oligodendrocyte dysfunction, with the retraction of myelinating processes. Consequently this demyelination causes myelin loss-induced axonal and neuronal degeneration that subsequently account for the onset of clinical symptoms [12].

**MYELIN PROTEIN FUNCTION**

Another important, yet under-studied aspect of MSA pathogenesis is myelin dysfunction. Myelin is a large modified membrane produced by oligodendrocytes that encases the axons of all neurons. It provides the insulation required to facilitate rapid signal transmission between neurons [44]. Critical to myelin function is membrane-associated proteins. These include proteolipid protein (PLP), which spans the myelin membrane bilayer, and myelin basic protein (MBP), which is located on the cytoplasmic surface of myelin membranes [45,46]. Together PLP and MBP constitute the majority of the total myelin proteins (85%). Furthermore, they are both located in the compact portion of myelin, which is where adjacent myelin layers become fused in forming the central segment of the myelin sheath, as opposed to the non-compact portion where layers do not fuse and form the periphery of the myelin sheath [47]. Here, PLP and MBP function to ensure the proper compaction of myelin layers and thus stabilize the ultrastructure of compact myelin [44]. More specifically, PLP stabilizes the intraperiod line (IPL) to maintain a separation between myelin layers, whereas MBP stabilizes the major dense line (MDL) to facilitate the adhesion of these layers [48,49].

Maintaining the necessary levels of MBP and PLP for the proper compaction of myelin is integral for normal myelination. This has been demonstrated through previous studies investigating the
myelination capabilities of PLP and MBP mutant mice, whereby mice exhibited defects in myelin compaction corresponding to the specific ultrastructure they are known to stabilize. That is, in both MBP and PLP mutant mice that have undetectable levels of the proteins, a complete absence of the MDL and IPL was observed respectively [50,51]. The detrimental effects resulting from the absence of these ultrastructures was subsequently exemplified by myelin instability in the form of dysmyelination (i.e. myelin is formed, but in an aberrant pattern) and hypomyelination (i.e. inability to form adequate amounts of myelin) in both PLP and MBP mutant mice [50,52]. Notably however, these abnormalities were more pronounced in MBP deleted mice [46,50], thus suggesting either MBP holds a more important role in myelination, or that other unknown molecules may compensate for the functional and structural consequences associated with the loss of PLP to consequently reduce the severity of myelin abnormalities [44]. Nonetheless, in conjunction with the trend of increasing myelination throughout life [53] and the requirement of continual myelin turnover to maintain neuronal networks even at older ages [54], it is clear retaining adequate levels of PLP and MBP is essential for both the maintenance and formation of myelin throughout life. Thus, reductions in the amount of these proteins in myelin could account for myelin dysfunction observed in MSA brains.

As suggested by the aforementioned studies, genetic mutations are one way in which the levels of MBP and PLP can be reduced. However, given the sporadic origin of MSA, this may be unlikely in MSA and hence, a more relevant mechanism could be through the disruption of their synthesis and subsequent transport from oligodendrocyte cell body to its myelin. The appropriate synthesis and subsequent transport of myelin constituents is of utmost importance, as different compartments of myelin (e.g. compact, non-compact) have different compositions required for executing their functions [55]. Furthermore, similar to their contrasting functions in myelination, the synthesis and transport pathways of MBP and PLP are also considerably different. That is, MBP mRNA is transcribed in the nucleus of oligodendrocytes and directly transported as mRNA granules towards myelin [56,57]. The protein synthesis of MBP then occurs de novo in myelin to prevent non-specific interaction during its transport to myelin, due to the highly adhesive properties of MBP in protein form [58,59]. In contrast, PLP protein is synthesized in the ER before being packaged into vesicles for transport to the Golgi apparatus [55,60]. From here, PLP indirectly reaches the myelin membrane by associating with a lipid raft domain of the oligodendrocyte membrane [61,62].

PROTEIN-LIPID INTERACTION IN MYELIN

Originally implicated in the transport of apical epithelial cell membrane constituents [61], lipid rafts are involved in the sorting of myelin constituents, as observed with PLP [60]. However, this is with an exception of MBP, as it does not appear to interact with lipid rafts for transport to myelin [55,59,63], although the MBP transcriptional regulator, fyn, is localized in lipid rafts [64,65]. Hence instead of transport, this suggests lipid rafts may indirectly influence the production of MBP by acting upstream of the protein itself. Nonetheless, the transport of PLP to myelin is assisted by lipid rafts being enriched in particular lipids, namely sphingomyelin and cholesterol, as studies have indicated protein-lipid interactions are essential for proper PLP transport. This includes the study by Kramer-Albers and colleagues [66], who used mice with missense mutations in the PLP gene that subsequently interfered with the ability of PLP to interact with cholesterol. Interestingly, this lack of a PLP-cholesterol association in mice consequently impeded their ability to transport PLP to lipid rafts [66]. Thus, since lipid rafts are required for the delivery of PLP to myelin, these findings were thought to disturb the delivery of PLP to myelin, to ultimately prevent the downstream compaction of myelin layers necessary for myelination. Furthermore, in vitro studies have also demonstrated the depletion of cholesterol is capable of abolishing PLP-lipid raft associations, with the inhibition of sphingomyelin synthesis exerting similar consequences [67]. Hence, disruption of these interactions, whether it is through alterations in myelin proteins or disrupted brain lipid homeostasis, could initiate myelin impairment in MSA. Therefore, with regards to the latter, given that members of the ATP-binding cassette (ABC) transporter family regulate brain lipid homeostasis, aberrant function in ABCA members could potentially contribute to myelin impairment and loss in MSA.

ATP-BINDING CASSETTE (ABC) TRANSPORTERS

ABC transporters are a large superfamily of transmembrane proteins involved in the active translocation of various substrates (e.g. lipids, ions, sugars and peptides) across membranes, by binding and utilizing ATP hydrolysis for energy [68]. Thus far, 48 transcriptionally active human ATP transporter genes have been identified, and are divided into the seven subfamilies designated ABCA to ABCG based on their sequence homology, gene structure and transmembrane domain [68,69]. ABCA transporters hold a specialized role in maintaining lipid homeostasis by transporting lipids across cellular membranes [69]. For example in the periphery, ABCAI mediates cholesterol efflux from peripheral
tissues to the lipid acceptor apolipoprotein A1 for subsequent liver metabolism [70], whereas ABCA3 transports phospholipids to lamellar bodies in lungs for the synthesis of pulmonary surfactants [71,72]. Furthermore, as genetic mutations in these ABCA transporters result in disorders such as Tangier’s disease and respiratory distress syndrome, respectively, this clearly exemplifies the importance of these transporters for the maintenance of lipid homeostasis [73,74]. These deleterious effects following dysfunctional lipid transport from ABCA gene mutations affects the central nervous system similarly.

ABCA8 IN THE EARLY STAGES OF MSA PATHOGENESIS

These findings suggestive of ABCA transporters being involved in the regulation of lipid homeostasis have recently been extended to the relatively unknown member ABCA8 [75], another putative brain lipid transporter of the ABCA subfamily [76]. Initial evidence suggestive of its role in regulating brain lipid homeostasis arose from its expression in the choroid plexus of adult mice [77] and in the human brain [75], along with its ability to transport the lipophilic substrate, leukotriene C4, across *Xenopus laevis* oocyte membranes [77]. A recent study by Kim and colleagues [75] has also provided the first in-depth functional study of ABCA8. Here, it was revealed ABCA8 specifically regulates sphingomyelin production in oligodendrocytes. Thus, given the necessity of sphingomyelin for the formation of lipid rafts to properly transport myelin constituents necessary for myelination [61], this suggested ABCA8 was involved in myelination. This was also consistent with the finding that ABCA8 expression correlated with the normal pattern of myelination throughout life [75], whereby it increases from neonatal periods to adulthood [53]. Additionally, the expression of ABCA8 was also highly elevated in the myelin-enriched white matter of the superior frontal lobe, in comparison to its grey matter counterpart, which also contains myelin, albeit to a much lesser degree [75]. Taken together, it was suggested ABCA8 appears to play a role in myelination through the regulation of sphingomyelin homeostasis. Therefore, in conjunction with the finding that ABCA8 expression is increased seven-fold in the brains of MSA patients in comparison to control brains [78], it is possible the dysregulation of lipid homeostasis could contribute to myelin dysfunction in the early stages of MSA. However, it remains to be determined whether ABCA8 is also capable of influencing other key myelin constituents such as MBP and PLP in carrying out this role, and whether their levels are altered by ABCA8 during MSA pathogenesis.

Besides myelination, recent evidence has also alluded to the involvement of ABCA8 in α-synuclein related pathogenic processes. This was suggested through the stimulation of the α-synuclein production upon overexpression of ABCA8 in cultured oligodendrocytes [78], thus suggesting a potential relationship between ABCA8 and α-synuclein production. If there is local aberrant α-synuclein synthesis in MSA oligodendrocytes following increased ABCA8 expression, the increased p25α expression that has been observed early in MSA [43] may stimulate the α-synuclein aggregation into GCIs [42]. Overall, these lines of evidence suggest ABCA8 is upregulated during the earlier stages of MSA, and may contribute to aberrant α-synuclein production and aggregation through dysregulated lipid homeostasis.

ACKNOWLEDGEMENTS

This work was supported by a National Health and Medical Research Council of Australia (NHMRC) project grants (#1022325). GMH is a NHMRC Senior Principal Research Fellow (#630434). Tissues were received from the Sydney Brain Bank at Neuroscience Research Australia and the New South Wales Tissue Resource Centre at the University of Sydney which are supported by the NHMRC, University of New South Wales, Neuroscience Research Australia, Schizophrenia Research Institute and National Institute of Alcohol Abuse and Alcoholism (NIH (NIAAA) R24AA012725).

REFERENCES


http://dx.doi.org/10.5607/en.2014.23.4.337


29. Campbell BC, McLean CA, Culveron JG, Gai WP, Blumbergs


53. Durston S, Hulshoff Pol HE, Casey BJ, Giedd JN, Buitelaar JK,


